Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer. 

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer

Maintenance selinexor improved progression-free survival in TP53 wild-type advanced endometrial cancer.

Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer

The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

Articles

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

 team as an assistant editor in 2025 after previously working on the 

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

OncLive News Network

Practical Application of Recent Clinical Data for Immunotherapy in NSCLC

Videos

Upfront PD-1 Inhibitor Monotherapy in Advanced NSCLC

Immunotherapy + Chemotherapy in Nonsquamous NSCLC

Combining Chemotherapy & Immunotherapy in Squamous NSCLC

TMB as a Predictive Biomarker in NSCLC

Treating Relapsed/Refractory NSCLC After I-O Therapy

Continuing/Re-Challenging With I-O Therapy in NSCLC

Experience With I-O Therapies in Second-Line NSCLC 

Immunotherapy in Locally Advanced NSCLC

Managing Pneumonitis in NSCLC

PD-L1 Expression in NSCLC

I-O Therapy Versus Surgery or Chemotherapy in NSCLC

Immunotherapy in NSCLC: Audience Q&A

Practical Application of Recent Clinical Data for Immunotherapy in NSCLC

Latest Conference Coverage